Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

February 2023

Efficacité et sécurité du bimekizumab dans la spondylarthrite axiale : Résultats de deux essais contrôlés randomisés de phase 3 menés en parallèle

Ann Rheum Dis. 2023 Jan 17 doi: 10.1136/ard-2022-223595

Vaux T,

Bimekizumab may therefore offer patients with axSpA an effective treatment option with a novel mode of action.

Keywords:

January 2023

Analyse des paramètres d'activité de la maladie dans une étude sur le retrait du méthotrexate chez des patients atteints de polyarthrite rhumatoïde traités par tofacitinib et méthotrexate

Rheumatol Ther. 2022. Epub ahead of print doi: 10.1007/s40744-022-00511-3

Fleischmann R,

Haraoui B,

Buch MH,

Gold D,

Sawyerr G,

Shi H,

Diehl A,

Lee K

This post hoc analysis of data from the ORAL Shift study, concludes that DAS28-4(ESR), CDAI remission and SDAI remission are the metrics most likely to reflect actual disease activity, in the context of tofacitinib in a randomised withdrawal of MTX.

Keywords:

November 2020

Incidence Basée sur l'Âge (<65 ans vs ≥65 ans) des Infections et des Infections Sévères avec le Tofacitinib versus les DMARD Biologiques dans les Essais Cliniques sur la Polyarthrite Rhumatoïde et le Registre Américain Corrona RA

Ann Rheum Dis 2020; DOI: 10.1136/annrheumdis-2020-218992

Gold D,

Shi H,

Reports from clinical trials and the US Corrona RA registry showed that serious infection event (SIE) incidence was higher in older versus younger patients with RA receiving 10 mg BID of TOF and ADA, however, SIE risk was similar between age groups with TOF 5 mg BID and ADA.Data were collected from Phase II–IV tofacitinib studies, and the US Corrona RA registry. The clinical data set evaluated patients receiving TOF 5 and 10 mg BID versus TNFi (ADA/ETN) in RA patients aged ≥50 years. The EMA rec...